TCT 2015: Heartflow’s FFR CT Could Bring Costs Down By One-Third
This article was originally published in Clinica
Executive Summary
HeartFlow’s FFR CT imaging system has demonstrated that it can pare off over 30% of the average cost of treating symptomatic patients at intermediate risk of coronary disease, while improving their quality of life. Experts who have reviewed the data from a cost and quality-of-life analysis of the PLATFORM trial caution, however, that this result will have to be confirmed in large randomized trials before FFR CT imaging supplants other types of noninvasive testing.
You may also be interested in...
£9m NHS Savings With HeartFlow 'Virtual FFR' Gets NICE Nod
UK's National Institute for Health and Care Excellence has recommended the HeartFlow FFRct Analysis for stable patients with a suspected myocardial infarction. NICE was won over by the potential £9m savings that the technology can bring to the National Health Services in the next five years.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.